United States
Print page content Print
Increase text size Decrease text size
Text Size

Rule out parasites

Rule out parasites

Don’t let fleas come between dogs and their
owners—protect the bond with SIMPARICA Simparica

Continue APOQUEL (oclacitinib tablet) and conduct a flea control trial
with SIMPARICA monthly chewables if you suspect flea allergy

Give dogs safe, persistent protection from fleas

In existing infestations, SIMPARICA starts killing fleas fast, within 3 hours—before they lay eggs

  • SIMPARICA keeps going strong for 35 days

3-month Flea Control Trial1

Conduct a 3-month flea control trial with SIMPARICA

Improve signs of Flea Allergy Dermatitis (FAD)

Studies showed improvement in clinical signs of FAD, including erythema, papules, scaling, alopecia, dermatitis/pyodermatitis and pruritus, as a direct result of
eliminating fleas.

Sarolaner Spinosad
Pruritus2
Animals With Signa at Day –1 or 0, n 78 31
Animals With Improvement in Signb at Day 90, n (%) 73 (93.6) 29 (93.5)
Erythema2
Animals With Signa at Day –1 or 0, n 80 35
Animals With Improvement in Signb at Day 90, n (%) 73 (91.3) 30 (85.7)
Alopecia (From Self-Trauma)2
Animals With Signa at Day –1 or 0, n 51 24
Animals With Improvement in Signb at Day 90, n (%) 47 (92.2) 22 (91.7)
Pruritus2
Sarolaner
Animals With Signa at Day –1 or 0, n 78
Animals With Improvement in Signb at Day 90, n (%) 73 (93.6)
Spinosad
Animals With Signa at Day –1 or 0, n 31
Animals With Improvement in Signb at Day 90, n (%) 29 (93.5)
Erythema2
Sarolaner
Animals With Signa at Day –1 or 0, n 80
Animals With Improvement in Signb at Day 90, n (%) 73 (91.3)
Spinosad
Animals With Signa at Day –1 or 0, n 35
Animals With Improvement in Signb at Day 90, n (%) 30 (85.7)
Alopecia (From Self-Trauma)2
Sarolaner
Animals With Signa at Day –1 or 0, n 51
Animals With Improvement in Signb at Day 90, n (%) 47 (92.2)
Spinosad
Animals With Signa at Day –1 or 0, n 24
Animals With Improvement in Signb at Day 90, n (%) 22 (91.7)

aClinical sign assessed as mild, moderate, or severe at screening visit.

bClinical sign decreased in severity at Day 90 relative to screening (Day -1 or 0).

SIMPARICA Indications: SIMPARICA kills adult fleas, and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis), and the treatment and control of tick infestations [Amblyomma americanum (lone star tick), Amblyomma maculatum (Gulf Coast tick), Dermacentor variabilis (American dog tick), lxodes scapularis (black-legged tick), and Rhipicephalus sanguineus (brown dog tick)] for one month in dogs 6 months of age or older and weighing 2.8 pounds or greater.

SIMPARICA Important Safety Information: Simparica is for use only in dogs, 6 months of age and older. Simparica may cause abnormal neurologic signs such as tremors, decreased conscious proprioception, ataxia, decreased or absent menace, and/or seizures. Simparica has not been evaluated in dogs that are pregnant, breeding or lactating. Simparica has been safely used in dogs treated with commonly prescribed vaccines, parasiticides and other medications. The most frequently reported adverse reactions were vomiting and diarrhea.

For more information, please see the full Prescribing Information.

APOQUEL Indications: Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

APOQUEL Important Safety Information: Do not use APOQUEL in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.

For more information, please see the full Prescribing Information.

CONVENIA Indications: CONVENIA is indicated for the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis.

CONVENIA Important Safety Information: People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to CONVENIA. Do not use in dogs or cats with a history of allergic reactions to penicillins or cephalosporins. Side effects for both dogs and cats include vomiting, diarrhea, decreased appetite/anorexia and lethargy.

For more information, please see the full Prescribing Information.

References: 1. Hensel P, Santoro D, Favrot C, et al. Canine atopic dermatitis: detailed guidelines for diagnosis and allergen identification. BMC Vet Res. 2015;11:196. doi:10.1186/s12917-015-0515-5. 2. Cherni J, Mahabir S, Six R. Efficacy and safety of sarolaner (SimparicaTM) against fleas on dogs presented as veterinary patients in the United States. Vet Parasitol. 2016;222:43-48.

The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
© 2018 Zoetis Services LLC. All rights reserved. CAD-00359